EGFR inhibitors effectively blocked feedback activation, and combined with Lenvatinib, produced synergistic antitumor effects, indicating that HCC patients with EGFRhigh could benefit from this combination (12, 15). This evidence concerns the gene EGFR and hepatocellular carcinoma.